🟢 Summit Therapeutics is trading 4.71% up in pre-market after major U.S. indexes rose overnight

Summit Therapeutics is trading at $18.69, up +4.71%, after a firm overnight market backdrop lifted major U.S. indexes.

• The S&P 500 rose 0.69% and Nasdaq Composite gained 1.07%, supporting biotechnology risk appetite
• No new company-specific announcement was identified for September 21, 2026
• Recent ivonescimab survival-data coverage dates to September 15; AstraZeneca licensing discussions are older and unconfirmed